Massachusetts Institute of Technology

Momenta Pharmaceuticals, Inc.

Istituto Di Ricerche Chimiche E Biochimiche G Ronzoni

Instituto Di Ricerche Chimiche E Biochimiche G. Ronzoni

Ganesh Venkataraman

Ram Sasisekharan

Zachary Shriver

Dongfang Liu

Rahul Raman

Mallikarjun Sundaram

Yiwei Qi

James R Myette

Nishla Keiser

Giangiacomo Torri

Benito Casu

Kevin Pojasek

Kristine Holley

Marco Guerrini

Yosuf El-Shabrawi

Robert Samuel Langer

Charles L Cooney

Nur Sibel Gunay

Ishan Capila

Xiangping Zhu

Corinne Bauer

Cuihua Liu

Maitland W McLean

Carlos J Bosques

Takashi Kei Kishimoto

Jonathan C Lansing

Daniela Beccati

Brian Edward Collins

Ian Christopher Parsons

Sucharita Roy

Viswanathan Sasisekharan

Dorota A Bulik

Rajeev Chillakuru

Lakshmanan Thiruneelakantapillai

Yiming Yao

Yi Wei Qi

Malikarjun Sundaram

Yi-Wei Qi

Thomas Richardson

Michele Picard

Steffen Ernst

Roy Sucharita

Ranganathan Godavarti

Pat Oliver-Shaffer

Ratnaleela Bobba

Zainab Sirajbhai Mamuwala

Ian David Fier

Ying Li

Maitland W Mclean

Yi Mei Qi

Liu Dongfang

Zachary Schriver

Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.

Saccharide structures and methods of making and using such structures

Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.

Low molecular weight heparin composition and uses thereof

The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.

Methods for analyzing a heparin sample

The presently disclosed subject matter provides methods for evaluating and characterizing peptides, peptide mixtures, and polypeptide mixtures. More particularly, the presently disclosed subject matter provides methods for evaluating or characterizing complex peptide or polypeptide mixtures comprising glutamic acid, alanine, tyrosine, and lysine, e.g., Copolymer-1 or glatiramer acetate, including, but not limited to, methods of identifying, isolating, quantifying, and purifying amino acids, peptides, polypeptides, and combinations thereof having a diethylamide group instead of a carboxyl group present on the C-terminus. The presently disclosed methods can be used to determine the mole percent of polypeptides having a diethylamide group at a C-terminus thereof and can be used to evaluate one or more properties of a sample of one polypeptide mixture as compared to one or more properties of a different sample of a polypeptide mixture.

Methods of evaluating diethylamide in glatiramer acetate

The present disclosure provides methods for assessing the glycosylation of a target glycoprotein produced by a cell through analysis of cell-surface glycans on the cell. The present disclosure therefore teaches that glycosylation of cell surface proteins can serve as a proxy for glycosylation of other proteins.

Methods related to cell surface glycosylation

The invention relates to methods and products for analyzing or processing a heparin sample. In one embodiment, the methods comprise contacting the sample with heparinase I, heparinase II and heparinase III, determining the amount of a signature component in the sample using a separation method, and making a determination about the sample based upon a comparison of the amount of the signature component in the sample to a reference database for a heparin.

Methods for analyzing or processing a heparin sample

Methods for analyzing mixtures of polysaccharides, for example heparin or a LMWH, using reduce end labeling are described. In general, the mixture of polysaccharides includes polysaccharides having a desired structural moiety. In some instances, one or more polysaccharides in the mixture are chemically modified prior to analysis.

Methods of evaluating mixtures of polysaccharides

The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis.

Method for sequence determination using NMR

The invention relates to &#x394;4,5 glycuronidase, related compositions, and methods of use thereof.

Delta 4,5 glycuronidase compositions and methods related thereto

The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.

Analysis of sulfated polysaccharides

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Modified heparinase III and methods of sequencing therewith

The invention relates to methods for delivering polysaccharides by a pulmonary route to achieve local and systemic therapeutic effects. The polysaccharides may be formulated or unformulated and in some instances have an extremely fast absorption rate.

Methods and products related to pulmonary delivery of polysaccharides

&#x394; 4,5 glycuronidase nucleic acid compositions

Growing community of inventors

Bedford, MA, United States of America

Ganesh Venkataraman